Institut Jerome Lejeune
11
2
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Genetic and Epigenetic Variations in Heterokaryotypic Monozygotic Twins Discordant for Down Syndrome
Role: lead
Genetic Markers and Biomarkers in Patients With Intellectual Disabilities of Genetic Origin
Role: lead
Anomalies of Nocturnal Gaz Exchanges in Patients With Down Syndrome
Role: lead
Early Detection and Treatment of Respiratory Sleep Disorders in Children With Down Syndrome
Role: lead
Cohort Study of Adult Patients With Down Syndrome at Risk of Developing Alzheimer's Disease (TriAL21)
Role: lead
Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS)
Role: collaborator
Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children
Role: lead
Down Syndrome and Continuous Positive Pressure Therapy
Role: lead
Correlations Phenotype / Genotype in Down Syndrome
Role: lead
Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome
Role: lead
Efficacy Study of Folinic Acid to Improve Mental Development of Children With Down Syndrome
Role: lead
All 11 trials loaded